0001104659-22-074822.txt : 20220627 0001104659-22-074822.hdr.sgml : 20220627 20220627165754 ACCESSION NUMBER: 0001104659-22-074822 CONFORMED SUBMISSION TYPE: 11-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220627 DATE AS OF CHANGE: 20220627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 11-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 221045375 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 11-K 1 tm2219370d1_11k.htm FORM 11-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 11-K

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________________ to _____________________

Commission File Number 1-2189

Full title of the plan and the address of the plan, if different from that of the issuer named below:

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

ABBOTT LABORATORIES

100 Abbott Park Road

Abbott Park, Illinois 60064-6049

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN

DECEMBER 31, 2021 AND 2020

C O N T E N T S

Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3

FINANCIAL STATEMENTS

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	5

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	6

NOTES TO FINANCIAL STATEMENTS	7

SUPPLEMENTAL SCHEDULE

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	17

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the “Plan”) as of December 31, 2021 and 2020, the related statement of changes in net assets available for benefits for the year ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2021 and 2020, and the changes in net assets available for benefits for the year ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2021 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ Grant Thornton LLP

We have served as the Plan’s auditor since 2002.

Chicago, Illinois

June 27, 2022

Abbott Laboratories Stock Retirement Plan
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2021 and 2020
(Dollars in thousands)

	2021		2020
Assets
Investments, at fair value	$	15,408,940	$	12,978,506
Notes receivable from participants		86,885		88,523
Accrued interest and dividend income		829		956
Due from brokers		189,159		142,584

Total assets		15,685,813		13,210,569

Liabilities
Investments sold short, at fair value		96,364		35,036
Accrued investment expenses		201		381
Due to brokers		202,357		93,367

Total liabilities		298,922		128,784

NET ASSETS AVAILABLE FOR BENEFITS	$	15,386,891	$	13,081,785

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Year ended December 31, 2021
(Dollars in thousands)

Additions
Contributions
Employer	$	176,564
Participant		338,466
Rollovers		57,626

Total contributions		572,656

Investment income
Net appreciation in fair value of investments		2,456,651
Interest and dividends		139,782

Net investment income		2,596,433

Interest income on notes receivable from participants		3,556

Total additions		3,172,645

Deductions
Benefits paid to participants		867,385
Other expenses		154

Total deductions		867,539

NET INCREASE		2,305,106

Net assets available for benefits
Beginning of year		13,081,785

End of year	$	15,386,891

The accompanying notes are an integral part of this statement.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS

December 31, 2021 and 2020

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “IRC”), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7). The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

In general, United States employees of Abbott Laboratories (“Abbott”) and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

Alight Solutions serves as the recordkeeper of the Plan. The Northern Trust Company (“Custodian” or “Trustee”) serves as the Plan’s custodian and trustee.

Contributions and Vesting

Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust (“Trust”). The Trust is administered by the Trustee and an investment committee (the “Committee”).

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate contribute from 2% up to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both. The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

Employer matching contributions to the Plan are made each payroll period based on the participating employee’s eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2021 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who makes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year. An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution. Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

Employer contributions are invested according to the participant’s investment elections.

Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

On January 1, 2013, Abbott separated into two publicly traded companies – Abbott and AbbVie Inc. ("AbbVie"). The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

	Vesting
Service	percentage
Less than two years		0%
Two years or more		100%

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65.

Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in employer contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, (2) pay Plan expenses and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2021, forfeitures reduced Abbott’s employer contributions by approximately $2.8 million. Approximately $2.1 million and $249,000 in forfeitures were available at the end of 2021 and 2020, respectively.

Distributions and In-Service Withdrawals

Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum. Participants may elect a direct rollover of their accounts. Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1^st of April following the year the participant reaches age 72 (or age 70 ½, if reached prior to January 1, 2020) or, if earlier, the 31^stof December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE A - DESCRIPTION OF THE PLAN - Continued

Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to IRC limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Investment Valuation

The Plan offers a variety of investment options to participants. Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock, mutual funds, REITs and futures contracts - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Participants are permitted to make redemptions from the funds on a daily basis. Certain funds require five days’ notice for a Plan level redemption. The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of $250,000 or 1% of the fund’s net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the funds in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind.

Corporate debt, government debt and other - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held. Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region’s market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond’s terms and conditions. Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

Certificate of deposit - Valued at amortized cost, which approximates fair value given the instruments’ short duration of less than 130 days.

Futures contracts

One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy. A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date. Futures contracts are exchange-traded and settle daily. Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract. Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

As of December 31, 2021 and 2020, the Plan held futures contracts with a notional amount of approximately $1.6 million and $2.2 million, respectively. Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts. The fair value of these derivative contracts was not material at December 31, 2021 and 2020. Changes in fair value are accounted for as investment income within net appreciation in fair value of investments and totaled approximately $717,000 for the year ended December 31, 2021.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Short sales

One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy. Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment. To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer. The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement. The price at such time may be more or less than the price at which the investment was sold by the separately managed account. When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2021 and 2020 (dollars in thousands):

	Basis of Fair Value Measurement
2021	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Assets - Investments:
Common stock	$	5,944,626	$	-	$	-	$	-	$	5,944,626
Mutual funds		125,728		-		-		-		125,728
REITs		29,984		-		-		-		29,984
Collective trust funds		-		-		-		8,416,720		8,416,720
Corporate debt		-		217,791		-		-		217,791
Government debt		-		195,521		-		-		195,521
Private 40-Act mutual funds		-		-		-		373,018		373,018
Other		-		105,552		-		-		105,552
Total investments at fair value	$	6,100,338	$	518,864	$	-	$	8,789,738	$	15,408,940

	Basis of Fair Value Measurement
2021	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Liabilities - Investments sold short:
Government debt	$	-	$	96,364	$	-	$	-	$	96,364
Total investments sold short at fair value	$	-	$	96,364	$	-	$	-	$	96,364

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

	Basis of Fair Value Measurement
	Quoted		Significant
	Prices in		Other		Significant
	Active		Observable		Unobservable		Measured at
2020	Markets		Inputs		Inputs		NAV		Total
Assets - Investments:
Common stock	$	4,819,600	$	-	$	-	$	-	$	4,819,600
Mutual funds		96,224		-		-		-		96,224
REITs		18,379		-		-		-		18,379
Collective trust funds		-		-		-		7,240,401		7,240,401
Corporate debt		-		242,622		-		-		242,622
Government debt		-		146,837		-		-		146,837
Certificate of deposit		-		4,509		-		-		4,509
Private 40-Act mutual funds		-		-		-		409,934		409,934
Total investments at fair value	$	4,934,203	$	393,968	$	-	$	7,650,335	$	12,978,506

	Basis of Fair Value Measurement
	Quoted		Significant
	Prices in		Other		Significant
	Active		Observable		Unobservable		Measured at
2020	Markets		Inputs		Inputs		NAV		Total
Liabilities - Investments sold short:
Government debt	$	-	$	35,036	$	-	$	-	$	35,036
Total investments sold short at fair value	$	-	$	35,036	$	-	$	-	$	35,036

The Private 40-Act mutual funds are not direct filing entities. These funds invest in fixed income instruments of varying maturities. The investment objective of one fund is to seek maximum current income and the other is to seek maximum total return, both being consistent with preservation of capital and liquidity.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan. No allowance for credit losses has been recorded as of December 31, 2021 or 2020.

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie stock. Investment fees for mutual funds, REITs, collective trusts, and managed accounts are charged against the net assets of the respective fund. Abbott pays other recordkeeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2021 and 2020 is presented below:

	2021		2020
Abbott common shares, 26,840,006 and 27,617,036 shares, respectively (dollars in thousands)	$	3,777,462	$	3,023,789
Market value per share	$	140.74	$	109.49

Abbott Laboratories Stock Retirement Plan

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Trustee and shares of the Trustee’s common stock. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2021, the Plan received $49.5 million in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the Trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

NOTE F - TAX STATUS

The Internal Revenue Service (“IRS”) has determined and informed Abbott by a letter dated May 19, 2017, that the Plan and related Trust are designed in accordance with applicable sections of the IRC. The Plan has been amended since the applicable date of the determination letter. However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021 and 2020, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits in progress.

NOTE G - RISKS AND UNCERTAINTIES

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

NOTE H - SUBSEQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2021 through the date these financial statements were issued. Other than disclosed below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

The Plan received an updated determination letter dated April 13, 2022 in which the IRS determined and informed Abbott that the Plan and related Trust are designed in accordance with applicable sections of the IRC.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - employer securities
*ABBOTT LABORATORIES, common shares		$	3,777,462

Common stock
5TH 3RD BANCORP			1,069
ABBVIE INC.			1,928,644
ACADIA HEALTHCARE CO INC COM			193
ACUITY BRANDS INC COM			263
ADAPTIVE BIOTECHNOLOGIES CORP COM			12
ADT INC DEL COM			48
ADVANCE AUTO PTS INC COM			544
AECOM			379
AES CORP COM			578
AFFILIATED MANAGERS GROUP INC COM STK			240
AFLAC INC COM			1,374
AGCO CORP COM			235
AGILENT TECHNOLOGIES INC COM			182
AGILON HEALTH INC COM			10
AIR LEASE CORP CL A			170
AKAMAI TECHNOLOGIES INC COM STK			677
ALASKA AIR GROUP INC COM			229
ALBEMARLE CORP COM			978
ALBERTSONS COS INC CL A			169
ALLEGHANY CORP DEL COM			284
ALLEGION PLC COMMON STOCK			102
ALLIANCE DATA SYS CORP COM			119
ALLIANT ENERGY CORP COM			553
ALLISON TRANSMISSION HOLDING			33
ALLY FINL INC COM			593
ALTICE USA INC CL A			36
AMCOR PLC ORD			666
AMDOCS ORD			348
AMEDISYS INC COM			22
AMER FINL GROUP INC OH COM STK			335
AMERCO COM			234
AMEREN CORP COM			815
AMERICAN AIRLINES INC COM			413
AMERICAN WTR WKS CO INC NEW COM			1,234
AMERIPRISE FINL INC COM			536
AMERISOURCEBERGEN CORP COM			710
AMETEK INC NEW COM			1,220
AMPHENOL CORP NEW CL A			531
ANSYS INC COM			734
ANTERO MIDSTREAM CORPORATION			116
APA CORP COM			351
APARTMENT INCOME REIT CORP COM			307
APOLLO			346
APTARGROUP INC COM			289
APTIV PLC COM USD			1,309
ARAMARK COM			304
ARCH CAPITAL GROUP COM STK			453
ARCHER-DANIELS-MIDLAND CO COM			1,355
ARDAGH METAL PACKAGING SA			45
ARES MANAGEMENT LP COM SHS REPSTG LTD PARTNER			50

Abbott Laboratories Stock Retirement Plan
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued
December 31, 2021
(Dollars in thousands)



Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
ARISTA NETWORKS INC COM			132
ARMSTRONG WORLD INDS INC NEW COM STK			103
ARROW ELECTR INC COM			334
ASHLAND GLOBAL HLDGS INC COM			213
ASSURANT INC COM			319
ASSURED GUARANTY LTD COMMON STK			122
ATMOS ENERGY CORP COM			488
AUTONATION INC COM			174
AUTOZONE INC COM			1,243
AVANGRID INC COM			103
AVERY DENNISON CORP COM			303
AVNET INC COM			147
AXALTA COATING SYSTEMS LTD COM			202
AXIS CAPITAL HOLDINGS LTD COM			152
AZEK CO INC CL A			85
AZENTA INC COM			48
BAKER HUGHES CO			638
BALL CORP COM			774
BANK OZK COM			203
BATH & BODY WORKS INC COM			259
BERKLEY W R CORP COM			409
BERRY GLOBAL GROUP INC			358
BEST BUY INC COM STK			691
BEYOND MEAT INC			16
BIO RAD LABORATORIES INC CL A			576
BIOMARIN PHARMACEUTICAL INC COM			580
BK HAW CORP COM			120
BLACK KNIGHT INC COM			453
BLOCK H & R INC COM			29
BOK FINL CORP COM NEW			114
BORG WARNER INC COM			388
BOYD GAMING CORP COM			152
BRIGHT HORIZONS FA COM			55
BRIGHTHOUSE FINL INC COM			148
BROADRIDGE FINL SOLUTIONS INC COM STK			70
BROOKFIELD RENEWABLE CORP CLASS A SUBORDINATE VOTING SHARES WI			127
BROWN & BROWN INC COM			558
BROWN FORMAN CORP CL A			56
BROWN-FORMAN INC CL B NON-VTG COM			242
BRUNSWICK CORP COM			243
BUILDERS FIRSTSOURCE INC COM STK			584
BUNGE LTD			462
BURLINGTON STORES INC COM			40
BWX TECHNOLOGIES INC COM			39
C H ROBINSON WORLDWIDE INC COM NEW			401
C3 AI INC CL A CL A			49
CABLE ONE INC COM			162
CACI INTL INC CL A CL A			225
CAESARS ENTMT INC NEW COM			260
CAMPBELL SOUP CO COM			305
CAPRI HOLDINGS LTD			345
CARDINAL HLTH INC			214
CARLISLE COMPANIES INC COM			283

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
CARLYLE GROUP INC COM			321
CARMAX INC COM			699
CARNIVAL CORP COM PAIRED			617
CARRIER GLOBAL CORPORATION COM			903
CARTER INC FORMERLY CARTER HLDGS INC TO 09/13/2003 COM			151
CASEYS GEN STORES INC COM			262
CATALENT INC COM			600
CBOE GLOBAL MARKETS INC			499
CBRE GROUP INC CL A CL A			1,235
CDK GLOBAL INC COM			150
CELANESE CORP DEL COM STK			419
CENTERPOINT ENERGY INC COM			596
CERIDIAN HCM HLDG INC COM			492
CERNER CORP COM			988
CERTARA INC COM			46
CF INDS HLDGS INC COM			545
CHANGE HEALTHCARE INC COM			192
CHARGEPOINT HOLDINGS INC COM			153
CHARLES RIV LABORATORIES INTL INC COM			43
CHEGG INC COM			38
CHEMED CORP NEW COM			211
CHEMOURS CO COM			95
CHURCH & DWIGHT INC COM			857
CIENA CORP COM NEW			427
CIN FNCL CORP COM			614
CINTAS CORP COM			88
CIRRUS LOGIC INC COM			188
CITIZENS FINL GROUP INC COM			595
CITRIX SYS INC COM			271
CLARIVATE PLC			368
CLEAN HBRS INC COM			182
CLEVELAND CLIFFS			357
CLOROX CO., COMMON STOCK			147
CLOUDFLARE INC COM			70
CMS ENERGY CORP COM			677
CNA FNCL CORP COM			44
COHERENT INC COM			24
COLFAX CORP COM			193
COLUMBIA SPORTSWEAR CO COM			129
COM ALCOA CORPORATION COM			400
COMERICA INC COM			410
COMM BANCSHARES INC COM			276
CONAGRA BRANDS INC COM			576
CONCENTRIX CORP			271
CONS EDISON INC COM			1,087
CONTINENTAL RES INC COM			94
COOPER COS INC COM NEW			730
COPA HOLDINGS SA COM STK			94
CORE & MAIN INC COM CL A			19
CORNING INC COM			675
CORTEVA INC COM			1,242
COSTAR GROUP INC COM			250
COTERRA ENERGY INC COM			457

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
COTY INC COM CL A			129
CRANE CO COM			180
CREDIT ACCEP CORP MICH COM			186
CROWN HLDGS INC COM			429
CULLEN / FROST BANKERS INC COM			259
CUMMINS INC			1,127
CURTISS WRIGHT CORP COM			195
D R HORTON INC COM			753
DARDEN RESTAURANTS INC COM			226
DARLING INGREDIENTS INC COMSTK			381
DATTO HLDG CORP COM			23
DAVITA INC COM			82
DECKERS OUTDOOR CORP COM			312
DEFINITIVE HEALTHCARE CORP CL A COM			7
DENTSPLY SIRONA INC COM			436
DEVON ENERGY CORP NEW COM			1,069
DIAMONDBACK ENERGY INC COM			369
DICKS SPORTING GOODS INC OC-COM OC-COM			260
DISCOVER FINL SVCS COM STK			548
DISCOVERY INC - A			140
DISCOVERY INC COM			260
DISH NETWORK CORP CL A COM STK			290
DIVERSEY HOLDINGS LTD COM			8
DOLBY LABORATORIES INC CL A COM STK			220
DOLLAR TREE INC COM STK			1,126
DOMINOS PIZZA INC COM			235
DONALDSON INC COM			231
DOORDASH INC CL A COM			94
DOVER CORP COM			938
DRIVEN BRANDS HLDGS INC COM			65
DT MIDSTREAM INC COM			167
DTE ENERGY CO COM			830
DUCK CREEK TECHNOLOGIES INC COM			60
DUN & BRADSTREET HLDGS INC COM			118
DXC TECHNOLOGY CO COM			291
DYNATRACE INC COM			25
EAGLE MATLS INC COM			238
EAST WEST BANCORP INC COM			399
EASTMAN CHEM CO COM			583
EDISON INTL COM			916
ELANCO ANIMAL HEALTH INC COM			455
ELEMENT SOLUTION INC COM			202
ENCOMPASS HEALTH CORP COM			98
ENTERGY CORP NEW COM			812
ENVISTA HLDGS CORP COM			261
EQT CORP COM			239
EQUIFAX INC COM			789
EQUITABLE HLDGS INC COM			428
ERIE INDTY CO CL A			54
ESSENTIAL UTILS INC COM			445
EURONET WORLDWIDE INC COM			63
EVERCORE INC			186
EVEREST RE GROUP COM			296

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
EVERGY INC COM NPV			565
EVERSOURCE ENERGY COM			1,124
EXACT SCIENCES CORP COM			36
EXELIXIS INC COM STK			29
EXPEDITORS INTL WASH INC COM			220
F N B CORP PA COM			139
F5 INC COM STK NPV			530
FACTSET RESH SYS INC COM STK			92
FASTENAL CO COM			150
FASTLY INC CL A CL A			135
FIDELITY NATL FINL INC			512
FIGS INC COM			73
FIRST AMERN FINL CORP COM STK			300
FIRST CTZNS BANCSHARES INC N C CL A			180
FIRST HAWAIIAN INC COM			126
FIRST HORIZON CORPORATION COM			315
FIRST REP BK SAN FRANCISCO CALIF NEW COM			1,324
FIRST SOLAR INC COM			332
FIRSTENERGY CORP COM			814
FLEETCOR TECHNOLOGIES INC COM			493
FLOWERS FOODS INC COM			185
FLOWSERVE CORP COM			143
FLUENCE ENERGY INC CL A			26
FMC CORP COM (NEW)			374
FOOT LOCKER INC COM			141
FORTIVE CORP COMMON STOCK			897
FORTUNE BRANDS HOME & SEC INC COM			388
FOX CORP CL A			422
FOX CORP CL B			186
FRKLN RES INC COM			348
FRONTDOOR INC COM			35
FTI CONSULTING INC COM			185
GALLAGHER ARTHUR J & CO COM			1,251
GAP INC COM			128
GARMIN LTD COMMON STOCK			742
GATES INDL CORP PL COM			55
GENPACT LIMITED COM STK			332
GENTEX CORP COM			297
GENUINE PARTS CO COM			703
GLOBALFOUNDRIES INC			58
GLOBE LIFE INC COM			338
GLOBUS MED INC CL A NEW COM STK			193
GODADDY INC CL A			460
GOHEALTH INC CL A			1
GRACO INC COM			184
GRAINGER W W INC COM			146
GRAND CANYON ED INC COM STK			122
GRAPHIC PACKAGING HLDG CO COM STK			142
GROCERY OUTLET HLDG CORP COM			89
GUIDEWIRE SOFTWARE INC COM			343
GXO LOGISTICS INC COM			45
HAIN CELESTIAL GROUP INC COM			140
HALLIBURTON CO COM			691

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
HANESBRANDS INC COM STK			84
HANOVER INS GROUP INC COM			168
HARLEY DAVIDSON COM			208
HARTFORD FINL SVCS GROUP INC COM			844
HASBRO INC COM			469
HAWAIIAN ELEC INDS INC COM			157
HAYWARD HLDGS INC COM			47
HEICO CORP NEW CL A			246
HEICO CORP NEW COM			157
HENRY SCHEIN INC COMMON STOCK			387
HERBALIFE NUTRITION LTD COM STK			125
HERSHEY COMPANY COM STK			145
HESS CORP COM STK			689
HEWLETT PACKARD ENTERPRISE CO COM			738
HEXCEL CORP NEW COM			156
HF SINCLAIR			176
HILTON WORLDWIDE HLDGS INC COM NEW			508
HOLOGIC INC COM			691
HORIZON THERAPEUTICS PLC			688
HORMEL FOODS CORP COM			497
HOWARD HUGHES CORP COM STOCK			152
HOWMET AEROSPACE INC COM			410
HP INC COM			1,021
HUBBELL INC COM			406
HUNT J B TRANS SVCS INC COM			69
HUNTINGTON BANCSHARES INC COM			797
HUNTINGTON INGALLS INDS INC COM			265
HUNTSMAN CORP COM STK			260
HYATT HOTELS CORP COM CL A			171
IAC/INTERACTIVECORP NEW COM			358
ICU MED INC COM			170
IDACORP INC COM			205
IDEX CORP COM			646
INCYTE CORP COM			70
INFORMATICA INC CL A			12
INGERSOLL RAND INC COM			903
INGREDION INC COM			233
INTEGRA LIFESCIENCES HLDG CORP COM DESP			174
INTERACTIVE BROKERS GROUP INC CL COM			229
INTERPUBLIC GROUP COMPANIES INC COM			528
INTL FLAVORS & FRAGRANCES INC COM			1,381
INTL PAPER CO COM			654
INVESCO LTD COM STK			276
IONIS PHARMACEUTICALS INC COM			12
IOVANCE BIOTHERAPEUTICS INC COM			71
IPG PHOTONICS CORP COM			208
IQVIA HLDGS INC COM			980
ITT INC COM			317
JABIL INC COM			77
JACK HENRY & ASSOC INC COM			328
JACOBS ENGR GROUP INC COM			647
JAMF HLDG CORP COM			11
JANUS HENDERSON GROUP PLC			255

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
JAZZ PHARMACEUTICALS PLC COM			275
JEFFERIES FINL GROUP INC COM			305
JETBLUE AWYS CORP COM			162
JONES LANG LASALLE INC COM STK			489
JUNIPER NETWORKS INC COM			417
KELLOGG CO COM			325
KEMPER CORP DEL COM			127
KEYCORP NEW COM			772
KEYSIGHT TECHNOLOGIES INC COM			773
KIRBY CORP COM			127
KKR & CO INC CL A			1,492
KNIGHT-SWIFT TRANSN HLDGS INC CL A			352
KOHLS CORP COM			266
KROGER CO COM			1,205
LAB CORP AMER HLDGS COM NEW			1,090
LAMAR ADVERTISING CO NEW CL A			47
LAMB WESTON HLDGS INC COM			234
LANDSTAR SYS INC COM			28
LAZARD LTD CL A			157
LEAR CORP COM NEW			395
LEGALZOOM COM INC COM			4
LEGGETT & PLATT INC COM			197
LEIDOS HLDGS INC COM			452
LEMONADE INC COM			52
LENNAR CORP CL A			1,119
LENNAR CORP CL B			54
LENNOX INTL INC COM			385
LESLIES INC COM			13
LIBERTY BROADBAND CORP COM SER A			136
LIBERTY BROADBAND CORP COM SER C			817
LIBERTY MEDIA CORP DEL COM SER A SIRIUSXM GROUP			169
LIBERTY MEDIA CORP DEL COM SER A FORMULAONE COM			54
LIBERTY MEDIA CORP DEL COM SER C SIRIUSXM GROUP			296
LIBERTY MEDIA CORPORATION COM SER C FORMULA			449
LINCOLN NATL CORP COM			374
LITHIA MTRS INC COM CL A			286
LITTELFUSE INC COM			271
LIVE NATION ENTERTAINMENT INC			366
LKQ CORP COM LKQ CORP			588
LOEWS CORP COM			444
LOUISIANA-PACIFIC CORP COM			229
LOYALTY VENTURES INC COM			22
LUMEN TECHNOLOGIES INC			461
LUMENTUM HLDGS INC COM			276
LYONDELLBASELL IND N V COM			765
M & T BK CORP COM			709
MADISON SQUARE GARDEN SPORTS CORP			73
MANDIANT INC COM			105
MANHATTAN ASSOCS INC COM			165
MANPOWERGROUP INC			190
MARATHON OIL CORP COM			458
MARATHON PETE CORP COM			1,416
MARKEL CORP HOLDING CO COM			500

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
MARRIOTT VACATIONS WORLDWIDE CORP COM			253
MARTIN MARIETTA MATLS INC COM			986
MARVELL TECHNOLOGY INC COM			2,579
MASCO CORP COM			615
MASIMO CORP COM STK			145
MASTEC INC COM			186
MC CORMICK & CO INC COM NON-VTG			867
MCAFEE CORP			18
MCKESSON CORP			1,171
MDU RES GROUP INC COM			224
MERCURY GEN CORP NEW COM			51
MERCURY SYSTEMS INC			111
MGIC INVT CORP WIS COM			168
MGM RESORTS INTERNATIONAL COM			630
MICROCHIP TECHNOLOGY INC COM			270
MIDDLEBY CORP COM			273
MIRATI THERAPEUTICS INC COM			37
MISTER CAR WASH INC COM			10
MKS INSTRS INC COM			54
MOHAWK INDS INC COM			360
MOLINA HEALTHCARE INC COM			560
MOLSON COORS BEVERAGE COMPANY COM CLASS B			298
MORNINGSTAR INC COM STK			27
MOSAIC CO/THE			525
MOTOROLA SOLUTIONS INC			1,625
MSA SAFETY INC COM			142
MSC INDL DIRECT INC CL A COM			136
MSCI INC COMMON			515
N V R INC COM			225
N-ABLE INC COM			16
NASDAQ INC			879
NATERA INC COM			19
NATIONAL INSTRS CORP COM			208
NATL FUEL GAS CO COM			201
NCR CORP COM			122
NEKTAR THERAPEUTICS COM			87
NETAPP INC COM STK			248
NEW YORK CMNTY BANCORP INC COM			198
NEW YORK TIMES CO CL A			287
NEWELL BRANDS INC COM			299
NEWMARKET CORP COM			80
NEWS CORP COM CL A			312
NEWS CORP COM CL B			97
NEXSTAR MEDIA GROUP INC CL A			199
NIELSEN HOLDINGS PLC COMSTK			264
NISOURCE INC COM			389
NORDSON CORP COM			442
NORDSTROM INC COM			14
*NORTHERN TR CORP COM			884
NORTONLIFE LOCK INC			378
NORWEGIAN CRUISE LINE HLDGS LTD COM			276
NOV INC COM			190
NRG ENERGY INC COM NEW			206

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
NUANCE COMMUNICATIONS INC			352
NUCOR CORP COM			1,174
NVENT ELECTRIC PLC COM			228
O REILLY AUTOMOTIVE INC NEW COM			1,177
OAK STR HEALTH INC COM			11
OCCIDENTAL PETROLEUM CORP			770
OGE ENERGY CORP COM			276
OLAPLEX HLDGS INC COM			68
OLD DOMINION FREIGHT LINE INC COM			104
OLD REP INTL CORP COM			248
OLIN CORP COM			275
OLLIES BARGAIN OUTLET HLDGS INC COM			120
OMNICOM GROUP INC COM			555
ON SEMICONDUCTOR CORP COM			475
ONEMAIN HLDGS INC COM			202
ONEOK INC COM STK			938
OPENDOOR TECHNOLOGIES INC COM			191
ORGANON & CO COM			278
ORION OFFICE REIT INC COM			37
OSHKOSH CORPORATION			277
OTIS WORLDWIDE CORP COM			1,333
OWENS CORNING NEW COM STK			326
PACCAR INC COM			1,082
PACKAGING CORP AMER COM			459
PACWEST BANCORP DEL COM			189
PARAMOUNT GLOBAL COM CL A			10
PARAMOUNT GLOBAL COM CL B			633
PARKER-HANNIFIN CORP COM			1,228
PAYCHEX INC COM			203
PAYCOR HCM INC COM			9
PAYSAFE LTD COM			98
PEGASYSTEMS INC COM			9
PENN NATL GAMING INC COM			288
PENSKE AUTOMOTIVE GROUP INC COM STK			119
PENTAIR PLC COM			434
PEOPLES UTD FINL INC COM			273
PERKINELMER INC COM			913
PERRIGO COMPANY LIMITED COM			187
PETCO HEALTH & WELLNESS CO INC CL A COM			37
PG& E CORP COM			660
PHILLIPS 66 COM			1,142
PILGRIMS PRIDE CORP			29
PINNACLE FINL PARTNERS INC COM			255
PINNACLE W. CAP CORP COM			286
PIONEER NAT RES CO COM			783
PLANET FITNESS INC CL A			85
POLARIS INC			69
POPULAR INC COM NEW COM			234
POST HLDGS INC COM STK			239
PPG IND INC COM			849
PPL CORP COM			814
PREMIER INC CL A			180
PRIMERICA INC COM			216

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
PRINCIPAL FINL GROUP INC COM STK			681
PROCORE TECHNOLOGIES INC COM			48
PROSPERITY BANCSHARES INC COM			232
PRUDENTIAL FINL INC COM			1,474
PUB SERVICE ENTERPRISE GROUP INC COM			1,211
PULTE GROUP INC			368
PURE STORAGE INC CL A			20
PVH CORP COM			273
QIAGEN NV			454
QORVO INC COM			624
QUANTA SVCS INC COM			584
QUANTUMSCAPE CORP COM			56
QUEST DIAGNOSTICS INC COM			759
QUIDEL CORP COM			178
QURATE RETAIL INC			99
RALPH LAUREN CORP CL A			205
RAYMOND JAMES FNCL INC COM STK			633
REGAL REXNORD CORPORATION COM STK			326
REGIONS FINL CORP NEW COM			754
REINSURANCE GROUP AMER INC COM NEW STK			267
RELIANCE STL & ALUM CO COM			364
RENAISSANCE RE HLDGS LTD COM			155
REPLIGEN CORP COM STK			30
REPUBLIC SVCS INC COM			1,055
RESMED INC COM			135
REYNOLDS CONSUMER PRODS INC COM			62
ROBERT HALF INTL INC COM			54
ROCKWELL AUTOMATION			573
ROLLINS INC COM			20
ROYAL CARIBBEAN GROUP COM STK			606
ROYAL GOLD INC COM STK			248
ROYALTY PHARMA PLC COM CLASS A			190
RPM INTL INC			193
RYDER SYS INC COM			155
S&P GLOBAL			1,786
S.W. AIRL CO COM			911
SAGE THERAPEUTICS INC COM			79
SANTANDER CONSUMER			91
SCHNEIDER NATL INC WIS CL B			50
SCIENCE APPLICATIONS INTL CORP			174
SEABOARD CORP DEL COM			35
SEAGEN INC COM			79
SEALED AIR CORP NEW COM STK			165
SEI INVTS CO COM			234
SENSATA TECHNOLOGIES B V HOLDING			345
SERVICE CORP INTL COM			410
SHOALS TECHNOLOGIES GROUP INC CL A			91
SIGNATURE BK NY N Y COM			690
SIGNIFY HEALTH INC CL A			33
SILGAN HLDGS INC COM			129
SIRIUS XM HLDGS INC COM			201
SITEONE LANDSCAPE SUPPLY INC COM			184
SIX FLAGS ENTMT CORP NEW COM			73

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
SKECHERS U S A INC CL A			183
SKYWORKS SOLUTIONS INC COM			486
SL GREEN RLTY			173
SLM CORP COM			207
SMITH A O CORP COM			409
SMUCKER J M CO COM NEW			513
SNAP-ON INC COM			414
SOLARWINDS CORP COM NEW COM NEW			18
SONOCO PROD CO COM			204
SPECTRUM BRANDS HLDGS INC			153
SPIRIT AEROSYSTEMS HLDGS INC CL A			115
SS&C TECHNOLOGIES HLDGS INC COM			661
STANLEY BLACK & DECKER INC COM			1,096
STATE STR CORP COM			1,222
STEEL DYNAMICS INC COM			342
STERICYCLE INC COM			196
STERIS PLC ORD			645
STIFEL FINL CORP COM			258
STONECO LTD COM CLASS A			9
SUNRUN INC COM			250
SVB FINANCIAL GROUP COMMON STOCK			1,382
SYLVAMO CORP COM			36
SYNCHRONY FINL COM			741
SYNEOS HEALTH INC COM			327
SYNOPSYS INC COM			737
SYNOVUS FINL CORP COM NEW			232
T ROWE PRICE GROUP INC			1,067
TAKE-TWO INTERACTIVE SOFTWARE INC			585
TANDEM DIABETES CARE INC COM			20
TAPESTRY INC COM			367
TARGA RES CORP COM			423
TD SYNNEX CORPORATION COM			171
TELADOC HEALTH INC			499
TELEDYNE TECHNOLOGIES INC COM			722
TELEFLEX INC COM			455
TERADATA CORP DEL COM STK			24
TERMINIX GLOBAL HLDGS INC COM			197
TEXTRON INC COM			612
TFS FINL CORP COM STK			32
THOR INDS INC COM STK			118
THOUGHTWORKS HLDG INC COM			27
TIMKEN CO COM			160
TOLL BROS INC COM			172
TOPBUILD CORP COM			57
TORO CO COM			20
TRADEWEB MKTS INC CL A			378
TRANE TECHNOLOGIES PLC COM			890
TRANSDIGM GROUP INC COM			843
TRANSUNION COM			259
TRAVEL + LEISURE CO COM			56
TRIMBLE INC COM TRIMBLE INC			786
TRIPADVISOR INC COM			38
TUSIMPLE HLDGS INC CL A			151

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
TWITTER INC COM			1,086
TYLER TECHNOLOGIES INC COM STK			104
TYSON FOODS INC CL A COM (DELAWARE)			901
UBIQUITI INC COM			8
UGI CORP NEW COM			343
ULTRAGENYX PHARMACEUTICAL INC COM			50
UMPQUA HLDGS CORP COM			149
UNDER ARMOR INC CL A			143
UNDER ARMOUR INC CL C COM			128
UNITED AIRLINES HOLDINGS INC COM			509
UNITED RENTALS INC COM			565
UNITED STS STL CORP NEW COM			229
UNITED THERAPEUTICS CORP DEL COM STK			343
UNIVAR SOLUTIONS INC			171
UNUM GROUP			180
UNVL HEALTH SERVICES INC CL B COM			332
US FOODS HLDG CORP COM			277
UWM HLDGS CORP COM CL A			10
V F CORP COM			305
VALERO ENERGY CORP COM STK NEW			1,104
VALMONT INDS INC COM			188
VALVOLINE INC COM			243
VERISIGN INC COM			888
VERISK ANALYTICS INC COM			474
VIASAT INC COM			111
VIATRIS INC			588
VICTORIAS SECRET & CO COM			63
VIMEO INC COM			7
VIRGIN GALACTIC HLDGS INC COM			7
VIRTU FINL INC CL A CL A			91
VISTRA CORP COM			392
VONTIER CORP COM			86
VOYA FINL INC COM			263
VROOM INC COM			34
VULCAN MATERIALS CO COM			988
WABTEC CORP COM			594
WATERS CORP COM			57
WATSCO INC COM			368
WAYFAIR INC CL A			232
WEBSTER FINL CORP			163
WEBSTER FNCL CORP WATERBURY CONN COM			181
WEC ENERGY GROUP INC COM			1,103
WESTERN ALLIANCE BANCORPORATION COM			185
WESTERN UNION CO			194
WESTLAKE CORPORATION COM			93
WESTN DIGITAL CORP COM			732
WESTROCK CO COM			421
WEX INC COM			74
WHIRLPOOL CORP COM			502
WHITE MOUNTAINS INSURANCE GROUP COM STOCK			106
WILLIAMS CO INC COM			1,139
WILLIAMS SONOMA INC COM			108
WILLIS TOWERS WATSON PLC COM			1,061

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Common stock - continued
WINTRUST FINL CORP COM			185
WOLFSPEED INC COM			464
WOODWARD INC COM			226
WORLD WRESTLING ENTMNT			11
WYNDHAM HOTELS & RESORTS INC COM			109
XCEL ENERGY INC COM			1,312
XEROX HLDGS CORP COM NEW COM NEW			116
XPO LOGISTICS INC COM			39
XYLEM INC COM			263
YUM BRANDS INC COM			1,342
YUM CHINA HLDGS INC COM			708
ZIMMER BIOMET HLDGS INC COM			954
ZIONS BANCORPORATION N A			350
ZYNGA INC			124
Total Common stock			5,944,626

Mutual funds
PIMCO ALL ASSET FUND			125,728

REITs
1ST INDL RLTY TR INC COM			306
AGNC INVT CORP COM			284
ALEXANDRIA REAL ESTATE EQUITIES INC COM			1,238
AMERICAN CAMPUS CMNTYS INC COM			282
AMERICAN HOMES 4 RENT COMMON STOCK			444
AMERICOLD RLTY TR COM			315
ANNALY CAP MGMT INC COM			393
AVALONBAY CMNTYS REIT			1,267
BRIXMOR PPTY GROUP INC COM			271
BSTN PPTYS INC			647
CAMDEN PPTY TR SH BEN INT			635
COUSINS PPTYS INC			215
CUBESMART			439
CYRUSONE INC COM			409
DOUGLAS EMMETT INC COM REIT			201
DUKE RLTY CORP COM NEW REIT			898
EPR PPTYS COM SH BEN INT COM SH BEN INT			126
EQTY LIFESTYLE PPTYS INC REIT			259
EQTY RESDNTL EFF 5/15/02			1,200
ESSEX PPTY TR REIT			821
EXTRA SPACE STORAGE INC COM			975
FEDERAL RLTY INVT			378
GAMING & LEISURE PPTYS INC COM			395
HEALTHCARE TR AMER INC CL A NEW			261
HEALTHPEAK PROPERTIES INC			700
HIGHWOODS PPTYS INC COM			165
HOST HOTELS & RESORTS INC REIT			442
HUDSON PACIFIC PROPERTIES INC COM			132
INVITATION HOMES INC COM			974
IRON MTN INC NEW COM			160
JBG SMITH PROPERTIES COM			126
KILROY RLTY CORP COM			278
KIMCO RLTY CORP COM			515

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
REITs - continued
LIFE STORAGE INC COM			449
MEDICAL PPTYS TR INC COM REIT			502
MID-AMER APT CMNTYS INC COM			952
NATIONAL RETAIL PPTYS INC COM STK			302
NEW RESIDENTIAL INVT CORP COM NEW			167
OMEGA HEALTHCARE INVS INC REIT			254
PARK HOTELS & RESORTS INC COM			160
RAYONIER INC REIT			206
REALTY INCOME CORP COM			1,457
REGENCY CTRS CORP COM			458
REXFORD INDL RLTY INC COM			442
SBA COMMUNICATIONS CORP CL A			1,263
SIMON PROPERTY GROUP INC COM			246
SPIRIT REALTY CAPITAL INC COM			213
STARWOOD PROPERTY TRUST INC COM REIT			253
STORE CAPITAL CORPORATION COM			302
SUN COMMUNITIES INC COM			865
UDR INC COM STK			664
VENTAS INC REIT			733
VICI PPTYS INC COM			682
VORNADO RLTY TR COM			264
W P CAREY INC COM			545
WELLTOWER INC COM REIT			1,344
WEYERHAEUSER CO COM			1,110
Total REITs			29,984

Collective trust funds
BLACKROCK INTERNATIONAL MULTI CAP EQUITY FUND			118,943
CAPITAL GROUP EUROPACIFIC GROWTH TRUST			428,094
CAPITAL GROUP GROWTH FUND OF AMERICA TRUST			1,265,898
CAPITAL GROUP WASHINGTON MUTUAL INVESTORS TRUST			328,782
GW&K SMALL-MID CAP CORE EQUITY FUND			187,488
*NORTHERN TRUST COLLECTIVE ACWI ex-U.S. INDEX FUND			138,855
*NORTHERN TRUST COLLECTIVE SHORT TERM INVESTMENT FUND			7,621
PIMCO TOTAL RETURN COLLECTIVE TRUST FUND			255,997
SSGA RUSSELL SMALL/MID CAP INDEX FUND CLASS K			914,424
SSGA S&P 500 INDEX FUND CLASS K			1,769,559
SSGA U.S. BOND INDEX FUND CLASS K			160,411
SSGA TARGET RETIREMENT 2020			250,337
SSGA TARGET RETIREMENT 2025			463,458
SSGA TARGET RETIREMENT 2030			487,753
SSGA TARGET RETIREMENT 2035			433,031
SSGA TARGET RETIREMENT 2040			354,507
SSGA TARGET RETIREMENT 2045			299,529
SSGA TARGET RETIREMENT 2050			220,136
SSGA TARGET RETIREMENT 2055			119,660
SSGA TARGET RETIREMENT 2060			53,256
SSGA TARGET RETIREMENT 2065			7,565
SSGA TARGET RETIREMENT INCOME			151,416
Total Collective trust funds			8,416,720

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Futures contracts
EQUITY FUTURES OFFSET - LONG			(1,611	)
FUT MAR 22 EMINI S&P 500			476
FUT MAR 22 IMM EMINI MDCP			1,135
Total Futures contracts			-

Corporate debt
AERCAP IRELAND CAP 4.625% DUE 07-01-2022			408
AERCAP IRELAND CAP DESIGNATED ACTIVITY C4.5% DUE 09-15-2023 REG			2,098
AERCAP IRELAND CAP/GLOBA 1.65% DUE 10-29-2024 BEO			3,195
AIR LEASE CORP MED 2.25% DUE 01-15-2023			2,227
AMERICAN ELEC PWR CO INC FLTG RT DUE 11-01-2023 REG			5,001
AMERN HONDA FIN FLTG RT 2.87288% DUE 06-27-2022			1,703
APIDOS CLO XXVII / APIDOS CLO XXVII SR SECD NT CL A-1R 144A 1.17129% 07-17-2030			3,791
AT&T INC FLTG RT 02-15-2023			1,207
ATMOS ENERGY CORP SR NT FLTG 1.02286% 03-09-2023			4,200
B A T CAP CORP 3.36738% 08-15-2022			6,516
BARCLAYS PLC SR NT FLTG VAR RT DUE 05-16-2024/05-16-2023			708
BOEING CO 1.875% DUE 06-15-2023			907
BOEING CO 4.508% DUE 05-01-2023			3,134
BRIXMOR OPER PARTNERSHIP LP FLTG 02-01-2022			1,001
CARLYLE GLOBAL MARKET STRATEGI 14/08/2030 0% 08-14-2030			3,792
CENTERPOINT ENERGY RES CORP DEL SR NT FLTG RATE 1.00429% 03-02-2023			1,696
CHARTER COMMUNICATIONS OPER LLC FRNS 02-01-2024			1,022
CMO WFRBS COML MTG TR 2013-C11 CL A-5 3.071% DUE 03-15-2045 REG			3,812
DAIMLER FIN NORTH AMER LLC CORP FLTG 144A 02-15-2022			2,002
DNB BK ASA MEDIUM VAR RT 1.12429% DUE 12-02-2022			502
DOMINION ENERGY INC FLTG RT DUE 09-15-2023			1,898
DUKE ENERGY CORP NEW SR NT FLTG 03-11-2022			1,301
ENBRIDGE INC FLTG 02-18-2022			5,002
FIRST ABU DHABI BK FR SNR EMTN 04/22			1,002
GEN MLS INC-MEDIUM TERM NTS-BOOK TRANCHE# TR 00148 6.41% 10-15-2022			1,881
GOLDMAN SACHS FLTG RT .946116% DUE 12-09-2026			3,419
GOLDMAN SACHS GROUP INC 1.217% 12-06-2023 BO			802
GS MTG BACKED SECS FLTG RT .89867% DUE 01-25-2052			2,897
KRAFT HEINZ FOODS CO GTD SR NT FLTG DUE 08-10-2022 REG			1,698
LCM XIII LTD PARTNERSHIP / LCM XIII 0% 07-19-2027			800
MFA 2020-NQM2 TR FLTG RT 1.381% DUE 04-25-2065			1,071
MITSUBISHI UFJ FINL GROUP INC SR NT FLTGDUE 07-26-2023 REG			2,048
MITSUBISHI UFJ FINL GROUP INC SR NT FLTGRATE DUE 07-25-2022 REG			3,064
MIZUHO FINL GROUP INC SR NT FLTG DUE 07-16-2023/07-16-2022 REG			2,206
NAVIENT PRIVATE ED LN TR 2020-I 1.39657%04-15-2069			2,241
NISSAN MOTOR ACCEPTANCE 2.6% DUE 09-28-2022			818
NISSAN MTR ACCEP CORP NT FLTG RATE 144A DUE 07-13-2022 BEO			1,001
NOMURA HLDGS INC 2.648% 01-16-2025			1,132
PAC GAS & ELEC CO 1.7% DUE 11-15-2023			1,403
PAC GAS & ELEC CO FIXED 1.75% DUE 06-16-2022			4,500
PAC GAS & ELEC CO FIXED 3.75% DUE 02-15-2024			207
PAC GAS & ELEC CO FLTG RT 2.36471% DUE 06-16-2022			1,800
PACIFIC GAS & ELEC CO 3.25% 06-15-2023			102
PACIFIC GAS & ELEC CO 3.4% 08-15-2024			310
PACIFIC GAS & ELECTRIC CO 3.85% 11-15-2023			103
PALMER SQUARE LN FDG 2021-3 LTD / SR SECD NT CL A-1 FLTG 144A .971 07-20-2029			3,796
PVPTL DAIMLER TRUCKS FLTG RT 12-14-2023			2,502

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Corporate debt - continued
PVTPL AMMC CLO 16 LTD/AMMC CLO 16 CORP SR SECD NT CL A-R2 FLTG 04-14-2029			3,229
PVTPL APIDOS CLO 17-26A A1AR FLTG 07-18-2029 USD			1,996
PVTPL AREIT 2020-CRE4 LTD/AREIT SR SECD NT CL SER 20-CRE4 CL A STEP 04-14-2037			540
PVTPL BAMLL COML MTG SECS SR 2019-AHT CL A FLTG 03-15-2034			699
PVTPL CBAM 2018-8 LTD LLC NT CL A-1 FLTG 3C7 10-20-2029 BEO			3,994
PVTPL CMO AREIT 2021-CRE5 LTD/AREIT AREIT 2021-C SR NT CL A VAR RT 07-17-2026			2,993
PVTPL CMO COLT 2021-4 MTG LN TR MTG PASSTHRU CTF CL A-1 10-25-2066			2,947
PVTPL CMO GOSFORTH FUNDING 2012-1 PLC STEP UP DUE 08-25-2060 BEO			172
PVTPL CMO MF1 2020-FL3 LTD SR SECD NT CL A FLTG 07-15-2035 BEO			828
PVTPL CMO WELLS FARGO COML MTG TR SER 2017-HSDB CL A VAR RT 12-13-2023			1,489
PVTPL CMO WELLS FARGO COMMERCIAL MTG TST SR 2012-C10 CL AFL VAR RT 09-15-2022			1,869
PVTPL CMO WFRBS COML MTG SER-2014-C21 CL-ASBF FLTG 08-16-2047 BEO			328
PVTPL DAIMLER FIN NORTH AMER LLC NT FLTG RATE 02-22-2022			5,005
PVTPL GPMT 2021-FL3 LTD/GPMT 2021-FL3 LLC SR SECD NT CL A FLTG 07-16-2035			1,743
PVTPL IMPERIAL TOBBACCO FINANCE 3.75% 07-21-2022			4,145
PVTPL KEB HANA BK SR NT FLTG DUE 10-02-2022 BEO			802
PVTPL KKR CLO 9 LTD / KKR CLO 9 LLC 15/07/2030 VAR RT DUE 07-15-2030 BEO			2,993
PVTPL MAGNETITE XVIII LTD/MAGNETITE XVIII LL SR16-18A CL AR2 VAR RT 11-15-2028			300
PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE LO SR 20-FL4 CL A VAR RT DUE 11-15-2035			2,420
PVTPL NAVIENT PRIVATE ED REFI LN TR 2021-G CL A 1.58% DUE 04-15-2070 BEO			2,292
PVTPL NAVIENT PRIVATE ED REFI LN TR SRS 20-HA CL A 1.31% DUE 01-15-2069			1,837
PVTPL NELNET STUDENT LN TR FLTG RT SER 19-2A CL A 06-27-2067 BEO			2,371
PVTPL OCTAGON INVT PARTNERS XXI LTD/OCTAGON SR SECD NT 02-14-2031			3,482
PVTPL PALMER SQUARE LN FDG 144A FLTG RT SER 19-3A CL A1 08-20-2027 BEO			1,602
PVTPL PALMER SQUARE LN FDG 2020-1 CL A1 FLTG RT DUE 02-20-2028			2,608
PVTPL SOCIAL PROFESSIONAL LOAN PROGRAM LL VAR RT DUE 10-25-2036 BEO			195
PVTPL SOUND PT CLO XVI LTD/SOUND PT CLO XVI VAR RT DUE 07-25-2030 BEO			1,999
PVTPL STANDARD CHARTERED PLC NT FLTG RATE 11-23-2025			4,601
PVTPL STRATUS CLO 2021-3 LTD/STRATUS CLO202 SR 21-3A CL A VAR RT DUE 12-29-2029			300
PVTPL TCW CLO SER 18-1A CL A1R FLTG 04-25-2031 BEO			299
PVTPL UBS AG LONDON BRH 09/02/2024 .45131% DUE 02-09-2024 BEO			700
PVTPL VENTURE CLO LTD SR 17-28A CL A2R VAR RT 07-20-2030			3,800
PVTPL VIBRANT CLO VI LTD SER 17-6A CL AR FLTG 06-20-2029			2,982
PVTPL VMC FIN 2021-FL4 LLC SR SECD NT CLA 144A FLTG RATE VAR RT DUE 06-16-2036			1,657
PVTPL VOLKSWAGEN GROUP AMER FIN LLC .75%DUE 11-23-2022 BEO			4,999
PVTPL VOYA CLO 2016-4 LTD/VOYA CLO SER 16-4A CL ARR FLTG RT DUE 07-20-2029			3,534
PVTPL Z CAP CR PARTNERS CLO SER 15-1A CL A1R FLTGT RT 07-16-2027			200
READY CAP MTG FING FLTG RT 1.45657% DUE 04-25-2038			1,964
ROYAL BK SCOTLAND FLTG RT 1.97643% DUE 05-15-2023			4,218
SARANAC CLO VI LTD / SARANAC CLO VI 1.94286000729% 08-13-2031			1,900
SOFI PROFESSIONAL LN PROGRAM 2020-C POSTGRADUATE LN AST BKD NT 1.95% 02-15-2046			1,916
SOUND PT CLO XV LTD / SOUND PT CLO SR SECD NT CL A-RR 144A 1.15886% 01-23-2029			3,995
SOUTHERN CALIF EDISON CO 1ST & REF MTG SER 2021 FLTG .711888% 04-03-2023			4,503
STD CHARTERED PLC FLTG RT 1.325839% DUE 10-14-2023			705
SUMITOMO MITSUI FINL GRP FLTG RT DUE 10-18-2022 BEO			2,411
SYNCHRONY BK 3% DUE 06-15-2022			1,009
THERMO FISHER SCIENTIFIC .797% 10-18-2023			5,481
TOWD PT MTG TR 2021-1 NT CL A1 144A 2.25% 11-25-2061			2,973
UBS GROUP FDG SWITZ AG NT FLTG 144A DUE 08-15-2023/08-15-2022 BEO			5,022
WELLS FARGO & CO NEW NT FLTG DUE 10-31-2023/10-31-2022 REG			2,016
WFRBS COML MTG TR 3.337% DUE 06-15-2046			3,802
Total Corporate debt			217,791

Abbott Laboratories Stock Retirement Plan

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR) - Continued

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
Description of asset/ Rate/ Maturity	Cost (a)	value
Government debt
FEDERAL HOME LN MTG CORP POOL #ZM5146 4%12-01-2047 BEO			357
FEDERAL HOME LN MTG CORP POOL #ZM6064 4%04-01-2048 BEO			50
FEDERAL HOME LN MTG CORP POOL #ZM8299 4%09-01-2048 BEO			285
FHLMC 4% MBS 01/01/2050 USD'SD-8039 POOL #SD8039 4 01-01-2050			222
FHLMC 4% MBS 01/06/2049 USD'ZT-2087 POOL #ZT2087 4 06-01-2049			288
FHLMC POOL #SD8006 4.0% 08-01-2049			171
FHLMC SD8012 4.0% 09-01-2049 BEO			9
GNMA 2016-H17 MTG PASS THRU CTF CL MX FC08-20-2066			629
GNMA 2016-H20 REMIC PASSTHRU CTF CL MX-PT 09-20-2066			1,323
GNMA REMIC PASSTHRU SER 2016-H11 CLS F 05-20-2066			125
UNITED STATES TREASURY NOTES 0.125% 11-30-2022			29,134
UNITED STATES TREASURY NOTES 1.125%NTS 08-31-2028 USD			3,435
UNITED STATES TREASURY NOTES .125% DUE 06-30-2022 REG			3,399
UNITED STATES TREASURY NOTES .625% 11-15-2024			11,040
UNITED STATES TREASURY NOTES .875% 12-15-2024			50,968
UNITED STATES TREASURY NOTES 30/11/2023 .5% DUE 11-30-2023 BEO			93,751
UNITED STATES TREAS BILLS 01-27-2022			335
Total Government debt			195,521

Private 40-Act mutual funds
PIMCO Short-Term Floating NAV Portfolio II			373,018

Other
KOMMUNEKREDIT 2.5% SNR EMTN 14/04/22 USD			8,049
METROPOLITAN TRANSN AUTH N Y REV .777% 11-15-2022 BEO TAXABLE			4,003
REPO W/BARCLAYS .02% FROM 12-31-2021 TO 01-03-2022			93,500
Total Other			105,552

*Loans to participants, 3.00% to 9.25%			86,885

		$	15,495,825

*Represents a party-in-interest transaction.

(a) Cost information omitted as all investments are fully participant directed.

FINANCIAL STATEMENTS AND

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ABBOTT LABORATORIES STOCK RETIREMENT PLAN (PUERTO RICO)

DECEMBER 31, 2021 and 2020

C O N T E N T S

	Page

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3

FINANCIAL STATEMENTS

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	5

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	6

NOTES TO FINANCIAL STATEMENTS	7

SUPPLEMENTAL SCHEDULE

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	15

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) as of December 31, 2021 and 2020, the related statement of changes in net assets available for benefits for the year ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2021 and 2020, and the changes in net assets available for benefits for the year ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

Supplemental information

/s/ GRANT THORNTON LLP

We have served as the Plan’s auditor since 2014.

Chicago, Illinois

June 27, 2022

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS

December 31, 2021 and 2020

(Dollars in thousands)

	2021		2020
Assets
Cash	$	9	$	4
Investments, at fair value		242,246		201,807
Notes receivable from participants		4,518		4,410
Due from brokers		1		4
Accrued interest income		4		3

Total assets		246,778		206,228

Liabilities
Accrued investment expenses		-		3
Due to brokers		303		15

Total liabilities		303		18

NET ASSETS AVAILABLE FOR BENEFITS	$	246,475	$	206,210

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

Year ended December 31, 2021

(Dollars in thousands)

Additions
Contributions
Employer	$	2,284
Participant		4,829

Total contributions		7,113

Investment income
Net appreciation in fair value of investments		39,255
Interest and dividends		4,571

Net investment income		43,826

Interest income on notes receivable from participants		178

Total additions		51,117

Deductions
Benefits paid to participants		10,844
Other expenses		8

Total deductions		10,852

NET INCREASE		40,265

Net assets available for benefits
Beginning of year		206,210

End of year	$	246,475

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS

December 31, 2021 and 2020

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan was established January 1, 2013 in conjunction with Abbott Laboratories (“Abbott”) separating into two publicly traded companies – Abbott and AbbVie Inc. (“AbbVie”). The Plan covers employees of Abbott’s selected subsidiaries and affiliates in Puerto Rico (the “Company”).

The Plan is a profit-sharing plan containing a cash or deferred arrangement intended to qualify for favorable tax treatment under sections 1081.01 (a) and (d) of the Puerto Rico Internal Revenue Code of 2011, as amended. In addition, the Plan provides an arrangement by which employees may invest in Abbott shares. Employees of the Company may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

The Plan’s sponsor is Abbott Healthcare (Puerto Rico) Ltd. Alight Solutions serves as the record keeper of the Plan. The Northern Trust Company (“Custodian”) and Banco Popular de Puerto Rico (“Trustee”) serve as the Plan’s custodian and trustee, respectively. The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

Contributions and Vesting

Contributions to the Plan are paid to a trust administered by the Trustee. An investment committee (the “Committee”) may direct the Trustee to establish investment options of the Committee’s choosing.

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate may contribute from 2% (or 1%, for Abbott Green participants) to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from either pretax earnings or after-tax earnings, or both. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contribution are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options, except for investment options closed to new contributions.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Employer matching contributions to the Plan are made each payroll period based on the participating employees’ eligible earnings. Excluding the Abbott Green participants, the employer contribution for the year ended December 31, 2021 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan. Effective with the first pay period ending after March 1, 2017, employer matching contributions for Abbott Green participants are made at the rate of 100% up to a 3% deferral of eligible earnings. Employer contributions are invested each pay period according to the participant’s investment elections.

In connection with the January 1, 2013 separation of Abbott into two publicly traded companies, Abbott shareholders received as a tax-free distribution one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Plan participants may continue to hold the AbbVie stock they received from the distribution; however, they may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan. AbbVie dividends are invested in the Plan’s default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other investment options available to the participants.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

	Vesting
Service	percentage
Less than two years		0%
Two years or more		100%

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65.

Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in matching contributions upon qualifying disability.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee’s termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, (2) pay Plan expenses and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2021, approximately $70,300 of forfeitures were used to reduce employer contributions. Forfeitures totaling approximately $181,000 and $117,900 were available at the end of 2021 and 2020, respectively.

Distributions and In-Service Withdrawals

Following retirement, termination or death, participants or their beneficiaries may elect to receive a distribution in installments, a single lump sum or a partial lump sum. Participants may elect a direct rollover of their accounts. Distribution must be made by the 1^stof April following the year the participant reaches age 72 (or age 70 ½, if reached prior to January 1, 2020) or, if earlier, the 31^stof December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including merged-in plan rollover accounts) and, after age 59 ½, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant’s account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, are subject to certain limitations.

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to $50,000, subject to Puerto Rico Internal Revenue Code limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee’s anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee’s anticipated retirement date, if sooner). Repayment is generally made through periodic payroll deductions or by sending in a payment, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

Investment Valuation

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock and mutual funds - Valued at the published market price per share or unit multiplied by the number of shares or units held.

Collective trust funds - Valued at the net asset value (“NAV”) provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Participants are permitted to make redemptions from the funds on a daily basis. Certain funds require five days’ notice for a Plan level redemption.

The following tables summarize the basis used to measure investments at fair value at December 31, 2021 and 2020 (dollars in thousands):

	Basis of Fair Value Measurement
2021	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Common stock	$	115,446	$	-	$	-	$	-	$	115,446
Mutual funds		45,416		-		-		-		45,416
Collective trust funds		-		-		-		81,384		81,384
Total investments at fair value	$	160,862	$	-	$	-	$	81,384	$	242,246

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

	Basis of Fair Value Measurement
2020	Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs		Measured at NAV		Total
Common stock	$	92,499	$	-	$	-	$	-	$	92,499
Mutual funds		13,336		-		-		-		13,336
Collective trust funds		-		-		-		95,972		95,972
Total investments at fair value	$	105,835	$	-	$	-	$	95,972	$	201,807

Notes Receivable from Participants

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie shares. Investment fees for mutual funds and collective trusts are charged against the net assets of the respective fund. The Company pays other record-keeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants’ common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2021 and 2020 is presented below:

	2021		2020
Abbott common shares, 594,382 and 605,942 shares, respectively (dollars in thousands)	$	83,653	$	66,345
Market value per share	$	140.74	$	109.49

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Custodian. A significant portion of the Plan’s assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2021, the Plan received $1,085,000 in common stock dividends from Abbott.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants’ account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant’s share in the trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

NOTES TO FINANCIAL STATEMENTS - CONTINUED

December 31, 2021 and 2020

NOTE F - TAX STATUS

The Plan received letters dated April 19, 2016 and December 2, 2019 from the Department of the Treasury of the Commonwealth of Puerto Rico that the Plan, as written, qualifies under Section 1081.01(a) of the Puerto Rico Internal Revenue Code of 2011, as amended and, consequently, its enabling trust is exempt from local income tax. The Plan has been amended since receiving the letters. The Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable Puerto Rico Internal Revenue Code.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2021 and 2020, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress.

NOTE G - RISKS AND UNCERTAINTIES

NOTE H - SUBSQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2021 through the date these financial statements were issued. Management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan (Puerto Rico)

SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)

December 31, 2021

(Dollars in thousands)

Identity of party involved/		Current
description of asset	Cost (a)	value
Common stock - employer securities
*Abbott Laboratories, common shares		$	83,653

Common stock
AbbVie Inc., common stock			31,793
Total Common stock			115,446

Mutual funds
American Funds EuroPacific Growth Trust			6,350
American Funds The Growth Fund of America Trust			18,369
American Funds Washington Mutual Investors Trust			4,090
PIMCO All Asset Fund			2,984
PIMCO Short Asset Investment Fund			9,743
Vanguard Mid-Cap Value Index Fund Admiral			3,880
Total Mutual funds			45,416

Collective trust funds
Blackrock International Opportunities Fund			2,464
GW&K Small-Mid Cap Core Equity Fund			4,600
*Northern Trust Collective ACWI ex-U.S. Index Fund			804
*Northern Trust Collective Short Term Investment Fund			546
PIMCO Total Return Collective Trust Fund			2,720
SSGA Russell Small/Mid Cap Index Fund			4,832
SSGA S&P 500 Index Fund			17,184
SSGA U.S. Bond Index Fund			1,030
SSGA Target Retirement 2020			4,970
SSGA Target Retirement 2025			8,703
SSGA Target Retirement 2030			8,317
SSGA Target Retirement 2035			6,333
SSGA Target Retirement 2040			5,870
SSGA Target Retirement 2045			4,210
SSGA Target Retirement 2050			2,636
SSGA Target Retirement 2055			1,447
SSGA Target Retirement 2060			315
SSGA Target Retirement 2065			9
SSGA Target Retirement Income			4,394
Total Collective trust funds			81,384

*Loans to participants, 3.21% to 5.50%			4,518

		$	246,764

*Represents a party-in-interest transaction.

(a) Cost information omitted as all investments are fully participant directed.

EXHIBIT INDEX

Exhibit No.	Exhibit

23.1	Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan.

23.2	Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan (Puerto Rico).

SIGNATURE

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

Date: June 27, 2022	By:	/s/ Sean J. Treacy
		Sean J. Treacy
		Plan Administrator

EX-23.1 2 tm2219370d1_ex23-1.htm EXHIBIT 23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated June 27, 2022, with respect to the financial statements and supplemental information included in the Annual Report of Abbott Laboratories Stock Retirement Plan on Form 11-K for the year ended December 31, 2021. We consent to the incorporation by reference of said report in the Registration Statement of Abbott Laboratories on Form S-8 as follows:

File No.		Effective Date
33-26685		January 23, 1989
33-504522		August 4, 1992
33-51585		December 20, 1993
33-56897		December 16, 1994
33-65127		December 18, 1995
333-19511		January 10, 1997
333-43383		December 29, 1997
333-69579		December 23, 1998
333-93257		December 21, 1999
333-74224		November 30, 2001
333-102180		December 23, 2002
333-109253		September 29, 2003
333-124849		May 12, 2005
333-141116		March 7, 2007
333-153198		August 26, 2008
333-169888		October 12, 2010
333-204772		June 5, 2015
333-227802		October 12, 2018
333-251335		December 14, 2020

/s/ Grant Thornton

Chicago, Illinois

June 27, 2022

EX-23.2 3 tm2219370d1_ex23-2.htm EXHIBIT 23.2

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We have issued our report dated June 27, 2022, with respect to the financial statements and supplemental information included in the Annual Report of Abbott Laboratories Stock Retirement Plan (Puerto Rico) on Form 11-K for the year ended December 31, 2021. We consent to the incorporation by reference of said report in the Registration Statement of Abbott Laboratories on Form S-8 as follows:

File No.		Effective Date
33-26685		January 23, 1989
33-504522		August 4, 1992
33-51585		December 20, 1993
33-56897		December 16, 1994
33-65127		December 18, 1995
333-19511		January 10, 1997
333-43383		December 29, 1997
333-69579		December 23, 1998
333-93257		December 21, 1999
333-74224		November 30, 2001
333-102180		December 23, 2002
333-109253		September 29, 2003
333-124849		May 12, 2005
333-141116		March 7, 2007
333-153198		August 26, 2008
333-169888		October 12, 2010
333-204772		June 5, 2015
333-227802		October 12, 2018
333-251335		December 14, 2020

/s/ Grant Thornton

Chicago, Illinois

June 27, 2022